GSK said it will not further develop its experimental drug for refractory chronic cough after failing to meet a key goal in a late-stage trial. The decision reduces near-term pipeline upside for this program and is a modest negative for the company’s therapeutic prospects in this indication.
GSK said it will not further develop its experimental drug for refractory chronic cough after failing to meet a key goal in a late-stage trial. The decision reduces near-term pipeline upside for this program and is a modest negative for the company’s therapeutic prospects in this indication.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
